ILUSTRASI. Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly US$ 40 billion. REUTERS/Mike Blake/Illustration/File Photo GLOBAL BUSINESS WEEK AHEAD - SEARCH GLOBAL BUSINESS 15 MAY FOR ALL IMAGES
Sumber: Wall Street Journal,Reuters | Editor: Anastasia Lilin Yuliantina
KONTAN.CO.ID - Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly US$ 40 billion or more. The Wall Street Journal reported on Wednesday.
The companies are discussing a price above US$ 200 a share for Seagen, the report said, citing people familiar with the matter.
Agar bisa lanjut membaca sampai tuntas artikel ini, pastikan Anda sudah berlangganan atau membeli artikel ini.
Sudah berlangganan? Masuk
Berlangganan Hanya dengan 20rb/bulan Anda bisa mendapatkan berita serta analisis ekonomi, bisnis, dan investasi pilihan
Business Insight, Epaper Harian + Tabloid, Arsip Epaper 30 Hari
Gratis uji coba 7 hari pertama. Anda dapat menggunakan akun Google sebagai metode pembayaran.
